Press release

DSM reports strong 2010 results and proposes dividend increase to €1.35

Heerlen, NL, 23 Feb 2011 07:15 CET

  • Vision 2010 strategy successfully completed; DSM will now drive focused growth
  • Q4 operating profit from continuing operations up 17% to €170 million
  • Full-year operating profit from continuing operations up 74% to €752 million
  • Very good Nutrition performance drives Life Sciences results
  • Significant improvement in Materials Sciences results
  • Continued strong cash flow from operating activities of €1.1 billion in 2010
  • Dividend increase of 12.5% to €1.35 per ordinary share proposed for 2010
  • 2011 is expected to be another strong year for DSM towards achieving the 2013 targets

Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said: “I am proud to report such strong financial results for 2010, which reflect our focus on innovation and our customers across the globe as well as cost and cash management supported by an improving economic climate. Within the Life Sciences businesses, our Nutrition business continued to record very good results, whilst Pharma needs improvement. The Materials Sciences businesses delivered a significant improvement during the year with a record result for Polymer Intermediates.

The year 2010 was the last in a period of transformation for DSM to become a focused Life Sciences and Materials Sciences company. We successfully completed our Vision 2010 strategy, including divesting the remaining non-core assets within the promised timescale. Subsequently, through a series of important transactions we have started to build additional strong growth platforms for the next phase of our strategy ‘DSM in motion: driving focused growth’ as evidenced by the announced acquisition of Martek and the announced joint venture with Sinochem for our anti-infectives business. We are confident that 2010 has laid the foundation for achieving our new strategic growth and profitability objectives and therefore we are proposing to raise our dividend from €1.20 to €1.35 instead of the €1.30 announced in September 2010.”

Key figures

Q4 2010 Q4 2009 +/- in € million FY 2010 FY 2009 +/-
      Continuing operations:      
2,082 1,758 18% Net sales 8,176 6,725 22%
276 260 6% Operating profit before depreciation & amortization (EBITDA) 1,161 834 39%
170 145 17% Operating profit (EBIT) 752 433 74%
136 137   Nutrition 569 521  
12 16   Pharma 7 32  
30 23   Performance Materials 179 68  
55 11   Polymer Intermediates 192 6  
-63 -42   Other activities -195 -194  
      Discontinued operations:      
120 258   Net sales 874 1,141  
14 15   Operating profit before depreciation & amortization (EBITDA) 117 83  
10 -3   Operating profit (EBIT) 86 10  
      Total DSM:      
2,202 2,016 9% Net sales 9,050 7,866 15%
180 142 27% Operating profit (EBIT) 838 443 89%
117 89   Net profit before exceptional items 547 244  
32 -149   Net result from exceptional items -40 93  
149 -60   Net profit 507 337  
      Net earnings per ordinary share in €:      
0.63 0.54   before exceptional items, continuing operations 2.89 1.44  
0.89 -0.39   including exceptional items, total DSM 3.03 2.01  

You can find the press release in full, including financial statements, below.

For more information

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420
media.contacts@dsm.com

Dave Huizing

Vice President Investor Relations
+31 45 578 2864
investor.relations@dsm.com

Media Relations

+31 45 578 2420

Investor Relations

+31 45 578 2864

This site uses cookies to store information on your computer.

Learn more